
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4765028/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof. Cardiovascular Drugs and Therapy, 2023, 37, 283-289.	2.6	2
2	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovascular Research, 2022, 118, 65-83.	3.8	14
3	Can low-grade renal artery stenosis be considered as cause for renovascular hypertension?. Journal of Human Hypertension, 2022, 36, 420-422.	2.2	2
4	Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP); study design of a multicentre randomized study. BMC Geriatrics, 2022, 22, 36.	2.7	6
5	Night shifts and hypertension. Journal of Clinical Hypertension, 2022, 24, 609-610.	2.0	2
6	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	3.8	33
7	The effect of medication on the aldosteroneâ€ŧoâ€ŧenin ratio. A critical review of the literature. Journal of Clinical Hypertension, 2021, 23, 208-214.	2.0	13
8	Home and office blood pressure: time to look at the individual patient. Hypertension Research, 2021, 44, 473-474.	2.7	1
9	Validating the RISE UP score for predicting prognosis in patients with COVID-19 in the emergency department: a retrospective study. BMJ Open, 2021, 11, e045141.	1.9	8
10	The anabolic role of the Warburg, Cori-cycle and Crabtree effects in health and disease. Clinical Nutrition, 2021, 40, 2988-2998.	5.0	30
11	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12
12	Confounders of the aldosteroneâ€ŧoâ€ŧenin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. Journal of Clinical Hypertension, 2021, 23, 201-207.	2.0	6
13	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	12.8	34
14	Value of biomarkers in predicting mortality in older medical emergency department patients: a Dutch prospective study. BMJ Open, 2021, 11, e042989.	1.9	0
15	Pharmacological and Nutritional Modulation of Vascular Calcification. Nutrients, 2020, 12, 100.	4.1	26
16	Do biomarkers add anything to clinical prediction of mortality in older medical emergency department patients?. European Journal of Internal Medicine, 2020, 81, 106-107.	2.2	2
17	Intact and C-Terminal FGF23 Assays—Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4875-e4885.	3.6	16
18	Enrichment of Rare Variants in Loeys–Dietz Syndrome Genes in Spontaneous Coronary Artery Dissection but Not in Severe Fibromuscular Dysplasia. Circulation, 2020, 142, 1021-1024.	1.6	30

#	Article	IF	CITATIONS
19	A new simplified model for predicting 30-day mortality in older medical emergency department patients: The rise up score. European Journal of Internal Medicine, 2020, 77, 36-43.	2.2	19
20	Pregnancy-Related Complications in Patients With Fibromuscular Dysplasia. Hypertension, 2020, 76, 545-553.	2.7	10
21	Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. American Heart Journal, 2020, 226, 60-68.	2.7	12
22	Glucocorticoids affect metabolic but not muscle microvascular insulin sensitivity following high versus low salt intake. JCI Insight, 2020, 5, .	5.0	12
23	Atherosclerotic Renovascular Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 21-32.	0.1	Ο
24	Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans. Journal of Bone and Mineral Research, 2020, 37, 1170-1178.	2.8	3
25	Drug-Resistant Hypertension. Hypertension, 2019, 73, 920-925.	2.7	3
26	Study protocol for a multicentre prospective cohort study to identify predictors of adverse outcome in older medical emergency department patients (the Risk Stratification in the Emergency Department) Tj ETQq	ე 0 . ე ფცე	/O v erlock 10
27	First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vascular Medicine, 2019, 24, 164-189.	1.5	232
28	Venous carbon dioxide embolism during laparoscopic cholecystectomy a literature review. European Journal of Internal Medicine, 2019, 60, 9-12.	2.2	19
29	First international consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2019, 37, 229-252.	0.5	80
30	Atherosclerotic Renal Artery Stenosis: Should we Intervene Earlier?. Current Hypertension Reports, 2018, 20, 35.	3.5	20
31	Disease or adaptation: another look at the practice of medicine. Postgraduate Medicine, 2018, 130, 239-243.	2.0	0
32	Aldosterone Is Not Associated With Metabolic and Microvascular Insulin Sensitivity in Abdominally Obese Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 759-767.	3.6	1
33	Framingham Stroke Risk Profile is related to cerebral small vessel disease progression and lower cognitive performance in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 240-245.	2.0	23
34	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. Journal of Hypertension, 2018, 36, 451-461.	0.5	19
35	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. Journal of Hypertension, 2018, 36, 462-471.	0.5	13
36	A sluice to normotension?. Journal of Hypertension, 2018, 36, 2314-2315.	0.5	0

#	Article	IF	CITATIONS
37	Hypertensive organ damage predicts future cognitive performance: A 9â€year followâ€up study in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 1458-1463.	2.0	6
38	Renal artery fibromuscular dysplasia and its effect on the kidney. Hypertension Research, 2018, 41, 639-648.	2.7	12
39	Differences in renal hemodynamics and renin secretion between patients with unifocal and multifocal fibromuscular dysplasia. Journal of Hypertension, 2018, 36, 1729-1735.	0.5	8
40	The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients. Hypertension Research, 2017, 40, 568-572.	2.7	3
41	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation. 2017. 32. 620-640.	0.7	133
42	The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension. Physiology, 2017, 32, 197-209.	3.1	103
43	Review: Targeting SBP lowering to <Â140 mm Hg reduces MACE more than targeting SBP to >Â140 in hypertensive patients ≥Â65 y. Annals of Internal Medicine, 2017, 166, JC55.	3.9	Ο
44	Pathophysiological differences between multifocal fibromuscular dysplasia and atherosclerotic renal artery stenosis. Journal of Hypertension, 2017, 35, 845-852.	0.5	12
45	Coronary Tortuosity: A Clue to the Diagnosis of Fibromuscular Dysplasia?. American Journal of Hypertension, 2017, 30, 776-780.	2.0	11
46	Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676.	0.5	56
47	MRI progression of cerebral small vessel disease and cognitive decline in patients with hypertension. Journal of Hypertension, 2017, 35, 1263-1270.	0.5	34
48	Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy. Hypertension, 2017, 69, 836-843.	2.7	96
49	An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. Journal of the American Society of Hypertension, 2017, 11, 81-91.	2.3	23
50	Dementia risk in renal dysfunction. Neurology, 2017, 88, 198-208.	1.1	103
51	Who removes the mask of hypertension?. Hypertension Research, 2017, 40, 964-965.	2.7	0
52	Reply. Journal of Hypertension, 2017, 35, 1721-1722.	0.5	0
53	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.5	0
54	Author response: Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies. Neurology, 2017, 89, 2214-2215.	1.1	0

#	Article	IF	CITATIONS
55	CD4+CD28null T Cells are related to previous cytomegalovirus infection but not to accelerated atherosclerosis in ANCA-associated vasculitis. Rheumatology International, 2017, 37, 791-798.	3.0	17
56	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.5	12
57	Arterial stiffness and decline of renal function in a primary care population. Hypertension Research, 2017, 40, 73-78.	2.7	28
58	Total Cerebral Small Vessel Disease MRI Score Is Associated with Cognitive Decline in Executive Function in Patients with Hypertension. Frontiers in Aging Neuroscience, 2016, 8, 301.	3.4	71
59	Renal hemodynamics and renin–angiotensin system activity in humans with multifocal renal artery fibromuscular dysplasia. Journal of Hypertension, 2016, 34, 1160-1169.	0.5	12
60	Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion. Journal of Hypertension, 2016, 34, 1607-1614.	0.5	1
61	Effect of increased protein intake on renal acid load and renal hemodynamic responses. Physiological Reports, 2016, 4, e12687.	1.7	10
62	Aldosterone–Renin Ratio and Side-Selective Renal Perfusion in Essential Hypertension. American Journal of Hypertension, 2016, 29, 1311-1316.	2.0	2
63	Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. Cmaj, 2016, 188, 91-92.	2.0	3
64	Sharing Clinical Trial Data. JAMA - Journal of the American Medical Association, 2016, 315, 467.	7.4	141
65	Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. Lancet, The, 2016, 387, e9-e11.	13.7	26
66	Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors. New England Journal of Medicine, 2016, 374, 384-386.	27.0	170
67	Atherosclerotic Renal Artery Stenosis and Hypertension: Pragmatism, Pitfalls, and Perspectives. American Journal of Medicine, 2016, 129, 635.e5-635.e14.	1.5	27
68	Endothelial Activation Is Associated With Cognitive Performance in Patients With Hypertension. American Journal of Hypertension, 2016, 29, 464-469.	2.0	25
69	Dietary proteins improve endothelial function under fasting conditions but not in the postprandial state, with no effects on markers of low-grade inflammation. British Journal of Nutrition, 2015, 114, 1819-1828.	2.3	9
70	Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial). Nutrients, 2015, 7, 8905-8915.	4.1	52
71	Sodium Intake as a Modulator of Kidney Function. Current Hypertension Reviews, 2015, 11, 57-60.	0.9	3
72	Baropacing as a new option for treatment of resistant hypertension. European Journal of Pharmacology, 2015, 763, 23-27.	3.5	5

#	Article	IF	CITATIONS
73	Unilateral baroreceptor activation therapy: the beauty of asymmetry. Expert Review of Cardiovascular Therapy, 2015, 13, 739-741.	1.5	1
74	Baroreflex Activation Therapy Lowers Arterial Pressure Without Apparent Stimulation of the Carotid Bodies. Hypertension, 2015, 65, 1217-1222.	2.7	18
75	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387.	2.8	15
76	Bilateral or Unilateral Stimulation for Baroreflex Activation Therapy. Hypertension, 2015, 65, 187-192.	2.7	60
77	The New ICMJE Recommendations. Indian Journal of Medical Microbiology, 2014, 32, 219-220.	0.8	5
78	Baroreflex activation therapy for patients with drug-resistant hypertension. Expert Review of Cardiovascular Therapy, 2014, 12, 955-962.	1.5	7
79	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension, 2014, 32, 1359-1366.	0.5	758
80	European consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2014, 32, 1367-1378.	0.5	154
81	Progression of Brain Microbleeds in Essential Hypertensive Patients: A 2-Year Follow-up Study. American Journal of Hypertension, 2014, 27, 1045-1051.	2.0	13
82	Treatment of Hypertension in the Oldest Old. Hypertension, 2014, 63, 433-441.	2.7	105
83	Subjective Cognitive Failures in Patients With Hypertension Are Related to Cognitive Performance and Cerebral Microbleeds. Hypertension, 2014, 64, 653-657.	2.7	49
84	Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. British Journal of Nutrition, 2014, 112, 600-608.	2.3	16
85	Angiotensin-(1-7) as a strategy in the treatment of hypertension?. Current Opinion in Nephrology and Hypertension, 2014, 23, 480-486.	2.0	15
86	Angiotensin-(1-7)-induced renal vasodilation is reduced in human kidneys with renal artery stenosis. Journal of Hypertension, 2014, 32, 2428-2432.	0.5	14
87	Basal Ganglia Enlarged Perivascular Spaces are Linked to Cognitive Function in Patients with Cerebral Small Vessel Disease. Current Neurovascular Research, 2014, 11, 136-141.	1.1	63
88	Treatment of Atherosclerotic Renal Artery Stenosis. JAMA - Journal of the American Medical Association, 2013, 309, 663.	7.4	19
89	Angiotensin-(1–7)–Induced Renal Vasodilation in Hypertensive Humans Is Attenuated by Low Sodium Intake and Angiotensin II Co-Infusion. Hypertension, 2013, 62, 789-793.	2.7	30
90	Blood Pressure Decreases More after High-Carbohydrate Meals Than after High-Protein Meals in Overweight Adults with Elevated Blood Pressure, but There Is No Difference after 4 Weeks of Consuming a Carbohydrate-Rich or Protein-Rich Diet. Journal of Nutrition, 2013, 143, 424-429.	2.9	10

#	Article	IF	CITATIONS
91	Salt and Sensitivity. Hypertension, 2013, 62, 461-462.	2.7	11
92	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension, 2013, 31, 1731-1768.	0.5	1,124
93	Renal Responses to Long-Term Carotid Baroreflex Activation Therapy in Patients With Drug-Resistant Hypertension. Hypertension, 2013, 61, 1334-1339.	2.7	36
94	Treatment of Renal Artery Stenosis—Reply. JAMA - Journal of the American Medical Association, 2013, 309, 2321.	7.4	0
95	Clinical end points in baroreflex activation therapy: what do we need to know?. Expert Review of Cardiovascular Therapy, 2013, 11, 683-688.	1.5	1
96	Blood pressure and renal function before and after percutaneous transluminal renal angioplasty in fibromuscular dysplasia. Journal of Hypertension, 2013, 31, 1183-1188.	0.5	10
97	Accumulation of MRI Markers of Cerebral Small Vessel Disease is Associated with Decreased Cognitive Function. A Study in First-Ever Lacunar Stroke and Hypertensive Patients. Frontiers in Aging Neuroscience, 2013, 5, 72.	3.4	159
98	Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. Annals of Internal Medicine, 2013, 158, JC7.	3.9	5
99	Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. American Journal of Physiology - Renal Physiology, 2012, 303, F149-F156.	2.7	20
100	Dual renin-angiotensin system blockade. BMJ: British Medical Journal, 2012, 344, e656-e656.	2.3	3
101	Determining the feasibility of objective adherence measurement with blister packaging smart technology. American Journal of Health-System Pharmacy, 2012, 69, 872-879.	1.0	28
102	Electronic Monitoring of Adherence, Treatment of Hypertension, and Blood Pressure Control. American Journal of Hypertension, 2012, 25, 54-59.	2.0	26
103	Accuracy of oscillometric blood pressure monitors for the detection of atrial fibrillation: a systematic review. Expert Review of Medical Devices, 2012, 9, 635-640.	2.8	23
104	Protein supplementation lowers blood pressure in overweight adults: effect of dietary proteins on blood pressure (PROPRES), a randomized trial. American Journal of Clinical Nutrition, 2012, 95, 966-971.	4.7	31
105	Baroreflex Activation Therapy for the Treatment of Drug-Resistant Hypertension: New Developments. Cardiology Research and Practice, 2012, 2012, 1-7.	1.1	21
106	Angiogenic T-Cells and Putative Endothelial Progenitor Cells in Hypertension-Related Cerebral Small Vessel Disease. Stroke, 2012, 43, 256-258.	2.0	50
107	Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. Journal of Hypertension, 2012, 30, 1665-1670.	0.5	20
108	Vascular inflammation in cerebral small vessel disease. Neurobiology of Aging, 2012, 33, 1800-1806.	3.1	175

#	Article	IF	CITATIONS
109	Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion, 2012, 52, 470-477.	1.6	67
110	Improved Cardiac Structure and Function With Chronic Treatment Using an Implantable Device in Resistant Hypertension. Journal of the American College of Cardiology, 2011, 57, 1787-1788.	2.8	77
111	Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension. Journal of the American College of Cardiology, 2011, 58, 765-773.	2.8	538
112	Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. Microvascular Research, 2011, 82, 77-83.	2.5	14
113	Obesity is associated with impaired endothelial function in the postprandial state. Microvascular Research, 2011, 82, 423-429.	2.5	28
114	Combination perindopril/indapamide for the treatment of hypertension: A review. Expert Opinion on Pharmacotherapy, 2011, 12, 1827-1833.	1.8	10
115	Subjective sleep disturbance increases the nocturnal blood pressure level and attenuates the correlation with target-organ damage. Journal of Hypertension, 2011, 29, 242-250.	0.5	16
116	Nycthemeral Relationship between Renal Function and Sodium Homeostasis. Current Hypertension Reports, 2011, 13, 136-141.	3.5	1
117	Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials, 2011, 12, 13.	1.6	37
118	Novel procedure- and device-based strategies in the management of systemic hypertension. European Heart Journal, 2011, 32, 537-544.	2.2	47
119	Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment. Hypertension, 2011, 58, 573-578.	2.7	100
120	Genetic variation in the renin—angiotensin system, use of renin—angiotensin system inhibitors and the risk of myocardial infarction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 208-214.	1.7	8
121	Resistance to antihypertensive treatment. Journal of Hypertension, 2011, 29, 1861-1862.	0.5	1
122	Meal-Related Increases in Microvascular Vasomotion Are Impaired in Obese Individuals. Diabetes Care, 2011, 34, S342-S348.	8.6	26
123	Does nocturnal blood pressure impair renal function?. Journal of Hypertension, 2010, 28, 430-431.	0.5	0
124	Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension. Journal of Hypertension, 2010, 28, 622-627.	0.5	34
125	Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial. Journal of Hypertension, 2010, 28, 865-874.	0.5	11
126	Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood, 2010, 115, 5121-5123.	1.4	113

#	Article	IF	CITATIONS
127	Carotid Baroreflex Activation: Past, Present, and Future. Current Hypertension Reports, 2010, 12, 61-66.	3.5	38
128	ASTRALogy: Unrealistic Expectations?. Current Hypertension Reports, 2010, 12, 143-145.	3.5	1
129	The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios: Results across Five Trial-Based Cost–Utility Studies. Value in Health, 2010, 13, 222-229.	0.3	58
130	Calcium scores and matrix Gla protein levels: association with vitamin K status. European Journal of Clinical Investigation, 2010, 40, 344-349.	3.4	55
131	Towards more uniform conflict disclosures: the updated ICMJE conflict of interest reporting form. Medical Journal of Australia, 2010, 193, 7-8.	1.7	1
132	Predictors of clinical outcome after stent placement in atherosclerotic renal artery stenosis: a systematic review and meta-analysis of prospective studies. Journal of Hypertension, 2010, 28, 2370-2377.	0.5	23
133	Assessing Medication Adherence Simultaneously by Electronic Monitoring and Pill Count in Patients With Mild-to-Moderate Hypertension. American Journal of Hypertension, 2010, 23, 149-154.	2.0	59
134	Toward More Uniform Conflict Disclosures. JAMA - Journal of the American Medical Association, 2010, 304, 212.	7.4	38
135	Toward more uniform conflict disclosures: updated ICMJE conflict of interest reporting form. Cmaj, 2010, 182, E425-E425.	2.0	3
136	Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients. Current Neurovascular Research, 2010, 7, 1-5.	1.1	9
137	Toward More Uniform Conflict Disclosures — The Updated ICMJE Conflict of Interest Reporting Form. New England Journal of Medicine, 2010, 363, 188-189.	27.0	76
138	Angiotensin II Enhances Insulin-Stimulated Whole-Body Glucose Disposal but Impairs Insulin-Induced Capillary Recruitment in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3901-3908.	3.6	23
139	Novel Baroreflex Activation Therapy in Resistant Hypertension. Journal of the American College of Cardiology, 2010, 56, 1254-1258.	2.8	321
140	Autoantibodies Against Oxidized Low-Density Lipoprotein in Cerebral Small Vessel Disease. Stroke, 2010, 41, 2687-2689.	2.0	28
141	Toward More Uniform Conflict Disclosures - The Updated ICMJE Reporting Form for Disclosure of Potential Conflicts of Interest. Revista Medica De Chile, 2010, 138, .	0.2	3
142	Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vascular Health and Risk Management, 2009, 5, 185.	2.3	376
143	Uniform Format for Disclosure of Competing Interests in ICMJE Journals. New England Journal of Medicine, 2009, 361, 1896-1897.	27.0	89
144	Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 101-108.	1.7	8

#	Article	IF	CITATIONS
145	Uniform format for disclosure of competing interests in ICMJE journals. Cmaj, 2009, 181, 565-565.	2.0	9
146	Variable hypertension and latent diabetes: two of a kind?. Journal of Hypertension, 2009, 27, 1536-1537.	0.5	1
147	Disclosure of competing interests. BMJ: British Medical Journal, 2009, 339, b4144-b4144.	2.3	6
148	Tomato Extract for Hypertension?. Cardiovascular Drugs and Therapy, 2009, 23, 107-108.	2.6	5
149	Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. International Journal of Clinical Pharmacy, 2009, 31, 158-164.	1.4	17
150	Reasons for nonâ€response in observational pharmacogenetic research. Pharmacoepidemiology and Drug Safety, 2009, 18, 665-671.	1.9	9
151	Improved Functional Capacity and Cardiovascular Structure after Baroreflex Activation Therapyâ,,¢ in Resistant Hypertension Patients with Symptomatic Heart Failure: Results from European and United States Trials of the Rheos® System. Journal of Cardiac Failure, 2009, 15, S63.	1.7	11
152	Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe Trial. International Journal of Cardiology, 2009, 137, S39-S40.	1.7	0
153	Variation in Renin-Angiotensin System and Salt-Sensitivity Genes and the Risk of Diabetes Mellitus Associated With the Use of Thiazide Diuretics. American Journal of Hypertension, 2009, 22, 545-551.	2.0	26
154	Renal Clearance of B-Type Natriuretic Peptide and Amino Terminal Pro-B-Type Natriuretic Peptide. Journal of the American College of Cardiology, 2009, 53, 884-890.	2.8	142
155	Doseâ€dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects. Blood Pressure, 2009, 18, 44-50.	1.5	44
156	Obtaining the family history for common, multifactorial diseases by family physicians. A descriptive systematic review. European Journal of General Practice, 2009, 15, 231-242.	2.0	20
157	Effects of Chronic Baroreceptor Stimulation on the Autonomic Cardiovascular Regulation in Patients With Drug-Resistant Arterial Hypertension. Hypertension, 2009, 54, 530-536.	2.7	156
158	The influence of six cardiovascular polymorphisms on a first event of ischemic heart disease is modified by sex and age. Coronary Artery Disease, 2009, 20, 499-505.	0.7	2
159	Interaction between the Gly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of Hypertension, 2009, 27, 61-68.	0.5	29
160	Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients. Journal of Hypertension, 2009, 27, 846-853.	0.5	47
161	Sex-specific effect of the α-adducin (G460W) and AGTR1 (A1166C) polymorphism on carotid intima–media thickness. Journal of Hypertension, 2009, 27, 2165-2173.	0.5	4
162	Associations of ambulatory blood pressure levels with white matter hyperintensity volumes in hypertensive patients. Journal of Hypertension, 2009, 27, 1446-1452.	0.5	47

#	Article	IF	CITATIONS
163	The association between arterial stiffness and the angiotensin II type 1 receptor (A1166C) polymorphism is influenced by the use of cardiovascular medication. Journal of Hypertension, 2009, 27, 69-75.	0.5	9
164	Prevalence, Causes, and Consequences of Masked Hypertension: A Meta-analysis. American Journal of Hypertension, 2008, 21, 969-975.	2.0	128
165	Improved Cardiac Structure and Function in Early-Stage Heart Failure with Chronic Treatment Using an Implantable Device: Results from European and United States Trials of the Rheos® System. Journal of Cardiac Failure, 2008, 14, S48.	1.7	10
166	Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. American Journal of Clinical Nutrition, 2008, 88, 1697-1702.	4.7	56
167	Response to Brain Microbleeds, Amyloid Plaques, Intellectual Deterioration, and Arterial Stiffness. Hypertension, 2008, 51, .	2.7	0
168	α-Adducin <i>Gly</i> 460 <i>Trp</i> Variant Increases the Risk of Stroke in Hypertensive Dutch Women. Hypertension, 2008, 51, 1665-1670.	2.7	23
169	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. Journal of Hypertension, 2008, 26, 1505-1526.	0.5	707
170	Rheos®Baroreflex Hypertension Therapy™ System to treat resistant hypertension. Expert Review of Medical Devices, 2008, 5, 33-39.	2.8	32
171	Brain Microbleeds Are Associated With Ambulatory Blood Pressure Levels in a Hypertensive Population. Hypertension, 2008, 51, 62-68.	2.7	94
172	Increased Aortic Pulse Wave Velocity Is Associated With Silent Cerebral Small-Vessel Disease in Hypertensive Patients. Hypertension, 2008, 52, 1120-1126.	2.7	251
173	The M235T Variant of the Angiotensinogen Gene Is Related to Development of Self-Reported Hypertension during Pregnancy: The Prospect-EPIC Cohort Study. Hypertension Research, 2008, 31, 1299-1305.	2.7	23
174	Renal Handling of Matrix Gla-Protein in Humans with Moderate to Severe Hypertension. Hypertension Research, 2008, 31, 1745-1751.	2.7	17
175	Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Pressure Monitoring, 2008, 13, 352-365.	0.8	48
176	Different classifications of nocturnal blood pressure dipping affect the prevalence of dippers and nondippers and the relation with target-organ damage. Journal of Hypertension, 2008, 26, 691-698.	0.5	61
177	Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. Journal of Hypertension, 2008, 26, 1328-1335.	0.5	57
178	Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and Genomics, 2008, 18, 631-636.	1.5	11
179	Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses. Vascular Health and Risk Management, 2008, Volume 4, 427-436.	2.3	34
180	The M235T Polymorphism in the AGT Gene and CHD Risk: Evidence of a Hardy-Weinberg Equilibrium Violation and Publication Bias in a Meta-Analysis. PLoS ONE, 2008, 3, e2533.	2.5	29

#	Article	IF	CITATIONS
181	Renal Artery Stenosis: Cost-effectiveness of Diagnosis and Treatment. Radiology, 2007, 244, 505-513.	7.3	19
182	Self-Measurement of Blood Pressure at Home Reduces the Need for Antihypertensive Drugs. Hypertension, 2007, 50, 1019-1025.	2.7	164
183	On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension. Archives of Internal Medicine, 2007, 167, 1884.	3.8	124
184	The trained observer better predicts daytime ambulatory blood pressure measurement diastolic blood pressure in hypertensive patients than does an automated (Omron)device. Blood Pressure Monitoring, 2007, 12, 57-59.	0.8	1
185	Masked hypertension, a review of the literature. Blood Pressure Monitoring, 2007, 12, 267-273.	0.8	36
186	Configuration of the microcirculation in pre-eclampsia: possible role of the venular system. Journal of Hypertension, 2007, 25, 1665-1670.	0.5	29
187	Renin-Angiotensin System and Nitric Oxide Synthase Gene Polymorphisms in Relation to Stroke. American Journal of Hypertension, 2007, 20, 764-770.	2.0	8
188	The impact of the journal and its impact on the journal. European Journal of Internal Medicine, 2007, 18, 171-172.	2.2	1
189	Editorial developments at the journal. European Journal of Internal Medicine, 2007, 18, 355-356.	2.2	Ο
190	Electronic Monitoring of Adherence as a Tool to Improve Blood Pressure ControlA Randomized Controlled Trial. American Journal of Hypertension, 2007, 20, 119-125.	2.0	53
191	Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients. Pharmacoeconomics, 2007, 25, 239-251.	3.3	27
192	Prevalence and Persistence of Masked Hypertension in Treated Hypertensive Patients. American Journal of Hypertension, 2007, 20, 1258-1265.	2.0	17
193	Masked Hypertension and White-Coat Hypertension Prognosis. Journal of the American College of Cardiology, 2006, 47, 2127.	2.8	14
194	Renal artery stenosis: today's questions. Current Opinion in Pharmacology, 2006, 6, 197-201.	3.5	2
195	Polymorphisms in human connexin40 gene promoter are associated with increased risk of hypertension in men. Journal of Hypertension, 2006, 24, 325-330.	0.5	64
196	The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. Journal of Hypertension, 2006, 24, 1541-1548.	0.5	66
197	A novel approach to the study of human microcirculation: reactivity to locally applied angiotensin II in the conjunctival microvascular bed. Journal of Hypertension, 2006, 24, 2225-2230.	0.5	12
198	Prevalence of the white-coat effect at multiple visits before and during treatment. Journal of Hypertension, 2006, 24, 2357-2363.	0.5	40

#	Article	IF	CITATIONS
199	Cost analysis of procedures related to the management of renal artery stenosis from various perspectives. European Radiology, 2006, 16, 154-160.	4.5	4
200	A Low Plasma Volume in Formerly Preeclamptic Women Predisposes to the Recurrence of Hypertensive Complications in the Next Pregnancy. Journal of the Society for Gynecologic Investigation, 2006, 13, 598-603.	1.7	34
201	Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension, 2005, 23, 2063-2070.	0.5	89
202	Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. Journal of Hypertension, 2005, 23, 753-758.	0.5	23
203	Neural activity of the cardiac baroreflex decreases with age in normotensive and hypertensive subjects. Journal of Hypertension, 2005, 23, 815-823.	0.5	39
204	Mechanisms of adenosine-induced renal vasodilatation in hypertensive patients. Journal of Hypertension, 2005, 23, 1731-1736.	0.5	16
205	Validation of a prediction rule for renal artery stenosis. Journal of Hypertension, 2005, 23, 1583-1588.	0.5	17
206	Genetic influences on 24???h blood pressure profiles in a hypertensive population: role of the angiotensin-converting enzyme insertion/deletion and angiotensin II type 1 receptor A1166C gene polymorphisms. Blood Pressure Monitoring, 2005, 10, 135-141.	0.8	8
207	Microvascular adaptation to changes in dietary sodium is disturbed in patients with essential hypertension. Journal of Hypertension, 2005, 23, 127-132.	0.5	9
208	Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundamental and Clinical Pharmacology, 2005, 19, 411-419.	1.9	71
209	Clonidine—Revisited, Relived or Time for Further Investigations?. Cardiovascular Drugs and Therapy, 2005, 19, 5-6.	2.6	0
210	Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?—Reply. Archives of Internal Medicine, 2005, 165, 1312.	3.8	1
211	Birth Weight and Creatinine Clearance in Young Adult Twins. Journal of the American Society of Nephrology: JASN, 2005, 16, 2471-2476.	6.1	34
212	A Subnormal Plasma Volume in Formerly Preeclamptic Women is Associated with a Low Venous Capacitance. Journal of the Society for Gynecologic Investigation, 2005, 12, 107-111.	1.7	34
213	Pre-pregnant Prediction of Recurrent Preeclampsia in Normotensive Thrombophilic Formerly Preeclamptic Women Receiving Prophylactic Antithrombotic Medication. Journal of the Society for Gynecologic Investigation, 2005, 12, 112-117.	1.7	8
214	Renal Contribution to Increased Clearance of Exogenous Growth Hormone in Obese Hypertensive Patients. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 795-799.	3.6	8
215	A116C Angiotensin II Type 1 Receptor Gene Polymorphism May Predict Hemodynamic Response to Losartan in Patients with Cirrhosis and Portal Hypertension. American Journal of Gastroenterology, 2005, 100, 2601-2602.	0.4	1
216	The Prothrombotic Paradox of Hypertension. Hypertension, 2005, 46, 1236-1242.	2.7	80

#	Article	IF	CITATIONS
217	OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics, 2005, 6, 755-775.	1.3	17
218	Formerly Preeclamptic Women With a Subnormal Plasma Volume Are Unable to Maintain a Rise in Stroke Volume During Moderate Exercise. Journal of the Society for Gynecologic Investigation, 2005, 12, 599-603.	1.7	17
219	Associations of the Angiotensin II Type 1 Receptor A ¹¹⁶⁶ C and the Endothelial NO Synthase G ⁸⁹⁴ T Gene Polymorphisms With Silent Subcortical White Matter Lesions in Essential Hypertension. Stroke, 2005, 36, 1869-1873.	2.0	57
220	Home Blood Pressure Measurement. Journal of the American College of Cardiology, 2005, 46, 743-751.	2.8	183
221	Clinical Significance of Renal Function in Hypertensive Patients at High Risk. Archives of Internal Medicine, 2004, 164, 2459.	3.8	95
222	Prognostic Significance of Electrocardiographic Voltages and Their Serial Changes in Elderly With Systolic Hypertension. Hypertension, 2004, 44, 459-464.	2.7	64
223	Reduced Uteroplacental Blood Flow Alters Renal Arterial Reactivity and Glomerular Properties in the Rat Offspring. Hypertension, 2004, 43, 1283-1289.	2.7	34
224	α-Adducin Gly460Trp Polymorphism and Renal Hemodynamics in Essential Hypertension. Hypertension, 2004, 44, 419-423.	2.7	32
225	Angiotensin II Sensitivity in Nonpregnant Formerly Preeclamptic Women and Halthy Parous Contorls. Journal of the Society for Gynecologic Investigation, 2004, 11, 416-422.	1.7	16
226	Genetic Risk of Atherosclerotic Renal Artery Disease. Hypertension, 2004, 44, 448-453.	2.7	10
227	Accuracy of Computed Tomographic Angiography and Magnetic Resonance Angiography for Diagnosing Renal Artery Stenosis. Annals of Internal Medicine, 2004, 141, 674.	3.9	313
228	Effects of nifedipine GITS and diuretics in isolated systolic hypertension - a subanalysis of the INSIGHT study. Blood Pressure, 2004, 13, 310-315.	1.5	14
229	Genetic predisposition to salt-sensitivity. Journal of Hypertension, 2004, 22, 1243-1249.	0.5	116
230	Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. Journal of Hypertension, 2004, 22, 81-87.	0.5	21
231	Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. Journal of Hypertension, 2004, 22, 847-857.	0.5	172
232	The Contribution of Risk Factors to Blood Pressure Heritability Estimates in Young Adults: The East Flanders Prospective Twin Study. Twin Research and Human Genetics, 2004, 7, 245-253.	1.0	7
233	Microvascular Abnormalities in Chronic Heart Failure: A Cross-Sectional Analysis. Microcirculation, 2003, 10, 471-478.	1.8	39
234	Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension. New England Journal of Medicine, 2003, 348, 2407-2415.	27.0	997

#	Article	IF	CITATIONS
235	Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 2003, 41, 431-436.	2.7	154
236	Is There a Side Predilection for Cerebrovascular Disease?. Hypertension, 2003, 42, 56-60.	2.7	109
237	Asymmetry of Renal Blood Flow in Patients With Moderate to Severe Hypertension. Hypertension, 2003, 41, 108-113.	2.7	30
238	Phase-Contrast Magnetic Resonance Flow Quantification in Renal Arteries. Hypertension, 2003, 41, 114-118.	2.7	22
239	Does Brain Natriuretic Peptide Have a Direct Renal Effect in Human Hypertensives?. Hypertension, 2003, 41, 119-123.	2.7	10
240	Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1206-H1212.	3.2	40
241	Renal protection from glomerular fibrosis. Journal of Hypertension, 2003, 21, 687-689.	0.5	Ο
242	Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population. Journal of Hypertension, 2003, 21, 81-86.	0.5	46
243	Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. Journal of Hypertension, 2003, 21, 2251-2257.	0.5	305
244	On the significance of renal vein renins in renovascular hypertension. Journal of Hypertension, 2002, 20, 843-845.	0.5	6
245	Chlamydia pneumoniae Seropositivity and Systemic and Renovascular Atherosclerotic Disease. Archives of Internal Medicine, 2002, 162, 786.	3.8	10
246	Predictive Value of Clinic and Ambulatory Heart Rate for Mortality in Elderly Subjects With Systolic Hypertension. Archives of Internal Medicine, 2002, 162, 2313.	3.8	254
247	Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, 2213-2222.	6.1	172
248	Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. Journal of Hypertension, 2002, 20, 2275-2283.	0.5	9
249	The Framingham prediction rule is not valid in a European population of treated hypertensive patients. Journal of Hypertension, 2002, 20, 1973-1980.	0.5	74
250	The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. Journal of Hypertension, 2002, 20, 2023-2027.	0.5	221
251	Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. Journal of Hypertension, 2002, 20, 493-499.	0.5	43
252	Effect of glycyrrhetinic acid on 11β-hydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects. Clinical Science, 2002, 102, 203.	4.3	9

#	Article	IF	CITATIONS
253	Blood pressure measurement in research. Blood Pressure Monitoring, 2002, 7, 83-87.	0.8	32
254	Ambulatory pulse pressure aspredictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, 835-843.	2.0	93
255	The Effects of Calcium Channel Blockers on Cardiovascular Outcomes: a Review of Randomised Controlled Trials. Blood Pressure, 2002, 11, 71-78.	1.5	14
256	Ambulatory and self-monitoring of blood pressure: Coming of age. Current Hypertension Reports, 2002, 4, 173-175.	3.5	0
257	Antihypertensive treatment and the kidney. Cardiovascular Drugs and Therapy, 2002, 16, 483-484.	2.6	0
258	Diagnostic Tests for Renal Artery Stenosis in Patients Suspected of Having Renovascular Hypertension. Annals of Internal Medicine, 2001, 135, 401.	3.9	336
259	Association between the α-adducin Gly460Trp polymorphism and systolic blood pressure in familial combined hyperlipidemia. American Journal of Hypertension, 2001, 14, 1185-1190.	2.0	22
260	Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Journal of Hypertension, 2001, 19, 511-519.	0.5	113
261	Preeclampsia and maladaptation to pregnancy: A role for atrial natriuretic peptide?. Kidney International, 2001, 60, 1397-1406.	5.2	53
262	The elderly hypertensive; cardiovascular and neurohormonal profile. Cardiovascular Drugs and Therapy, 2001, 15, 263-267.	2.6	7
263	Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension. Journal of Hypertension, 2000, 18, 963-969.	0.5	2
264	Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovascular Drugs and Therapy, 2000, 14, 49-53.	2.6	18
265	Influence of Diabetes and Type of Hypertension on Response to Antihypertensive Treatment. Hypertension, 2000, 35, 1038-1042.	2.7	98
266	Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension. Circulation, 2000, 102, 1139-1144.	1.6	271
267	Angiotensin II Sensitivity Is Associated With the Angiotensin II Type 1 Receptor A1166C Polymorphism in Essential Hypertensives on a High Sodium Diet. Hypertension, 2000, 36, 411-416.	2.7	100
268	Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, The, 2000, 356, 366-372.	13.7	1,156
269	How do angiotensin II receptor antagonists affect blood pressure?. American Journal of Cardiology, 1999, 84, 5-6.	1.6	8
270	On sleep and death: cardiovascular risk of the obstructive sleep apnea syndrome. Netherlands Journal of Medicine, 1999, 54, 188-190.	0.5	0

#	Article	IF	CITATIONS
271	Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. Journal of Hypertension, 1999, 17, 873-881.	0.5	68
272	Interpretation of renal angiography by radiologists. Journal of Hypertension, 1999, 17, 1737-1741.	0.5	27
273	Persistent abnormalities in plasma volume and renal hemodynamics in patients with a history of preeclampsia. American Journal of Obstetrics and Gynecology, 1998, 179, 690-696.	1.3	30
274	Calcium Channel Blockade and Cardiovascular Prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension, 1998, 32, 410-416.	2.7	66
275	Colonization with Pseudomonas aeruginosa in Patients Developing Ventilator-Associated Pneumonia. Infection Control and Hospital Epidemiology, 1998, 19, 853-855.	1.8	19
276	Dissociation between the renal effects of angiotensin I and II in sodium-restricted normal subjects. Cardiovascular Research, 1998, 38, 215-220.	3.8	7
277	Is nondipping in 24 h ambulatory blood pressure related to cognitive dysfunction?. Journal of Hypertension, 1998, 16, 1425-1432.	0.5	27
278	Microvascular effects of atrial natriuretic peptide (ANP) in man: studies during high and low salt diet. Cardiovascular Research, 1998, 39, 442-450.	3.8	17
279	Hypertension and the Development of Heart Failure. Journal of Cardiovascular Pharmacology, 1998, 32, S9-S15.	1.9	12
280	Comparison of different fixed antihypertensive combination drugs. Journal of Hypertension, 1997, 15, 87-91.	0.5	30
281	Can the blood pressure predict cognitive task performance in a healthy population sample?. Journal of Hypertension, 1997, 15, 1069-1076.	0.5	65
282	Acetylcholine-induced vasodilatation in the human hypertensive kidney. Journal of Hypertension, 1997, 15, 1649-1651.	0.5	8
283	Drug-Induced Hypertension. Drugs and Aging, 1997, 11, 178-185.	2.7	4
284	Is a Series of Blood Pressure Measurements by the General Practitioner or the Patient a Reliable Alternative to Ambulatory Blood Pressure Measurement? A Study in General Practice With Reference to Short-term and Long-term Between-Visit Variability. American Journal of Hypertension, 1997, 10, 879-885.	2.0	32
285	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, The, 1997, 350, 757-764.	13.7	2,841
286	Thin GBM nephropathy: Premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney International, 1997, 51, 1596-1601.	5.2	108
287	Natriuretic effect of nitrendipine is preceded by transient systemic and renal hemodynamic effects. Cardiovascular Drugs and Therapy, 1997, 11, 33-38.	2.6	5
288	Effects of antihypertensive drugs on various aspects of renal function. Cardiovascular Drugs and Therapy, 1997, 10, 803-808.	2.6	1

#	Article	IF	CITATIONS
289	Sensitivity of Blood Pressure and Renin Activation During Sodium Restriction. Hypertension, 1997, 30, 1216-1222.	2.7	10
290	Nonsteroidal Anti-Inflammatory Drugs and Hypertension. Drugs, 1996, 51, 179-187.	10.9	74
291	A prospective study of the natural history of idiopathic non-proteinuric hematuria. Kidney International, 1996, 49, 222-225.	5.2	39
292	Renal Extraction of Atrial Natriuretic Peptide in Hypertensive Patients With or Without Renal Artery Stenosis. Hypertension, 1996, 27, 1254-1258.	2.7	2
293	Does nitric oxide synthesis really contribute to systemic blood pressure control? ??? Reply. Journal of Hypertension, 1995, 13, 1221.	0.5	Ο
294	Quantitative analysis of retinal vascular changes in essential and renovascular hypertension. Journal of Hypertension, 1995, 13, 1729???1733.	0.5	39
295	Circulating adrenaline is not involved in the circadian blood pressure profile. Journal of Hypertension, 1995, 13, 1585???1588.	0.5	Ο
296	Does nitric oxide synthesis really contribute to systemic blood pressure control?. Journal of Hypertension, 1995, 13, 709.	0.5	1
297	Selective Enhancement of α2-Adrenoceptor-Mediated Vasoconstriction in Insulin-Dependent Diabetic Patients with Microalbuminuria. Clinical Science, 1995, 88, 421-426.	4.3	12
298	Vascular compliance in sodium-sensitive and sodium-resistant borderline hypertensive patients. Kidney International, 1995, 47, 169-176.	5.2	3
299	Trandolapril: A Clinical Profile. American Journal of Hypertension, 1995, 8, 68S-70S.	2.0	4
300	Trough-To-Peak Versus Surface Ratio in the Assessment of Antihypertensive Agents. Blood Pressure, 1995, 4, 350-357.	1.5	12
301	Influence of Interdialytic Weight Gain on Blood Pressure in Hemodialysis Patients. Blood Purification, 1994, 12, 259-266.	1.8	47
302	Doxazosin versus nitrendipine: A double-blind comparative study in patients adhering to a sodium-restricted diet. Cardiovascular Drugs and Therapy, 1994, 8, 473-477.	2.6	2
303	Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. Journal of the American College of Cardiology, 1994, 23, 82-91.	2.8	39
304	Differential tissue expression of Annexin VIII in human. FEBS Letters, 1994, 349, 120-124.	2.8	26
305	Hemodynamic, Neurohumoral, and Myocardial Energetic Effects of Pimobendan, a Novel Calcium-Sensitizing Compound, in Patients with Mild to Moderate Heart Failure. Journal of Cardiovascular Pharmacology, 1994, 24, 730-739.	1.9	25
306	SHORT-TERM RENAL HEMODYNAMIC CHANGES IN PATIENTS RECEIVING A RENAL ALLOGRAFT. Transplantation, 1994, 57, 1661-1663.	1.0	1

#	Article	IF	CITATIONS
307	Nailfold capillary density in salt-sensitive and salt-resistant borderline hypertension. Journal of Hypertension, 1993, 11, 1195???1198.	0.5	3
308	Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertension. Journal of Hypertension, 1993, 11, 1199???1208.	0.5	24
309	Renal function in the elderly: Results from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine, 1991, 90, S45-S49.	1.5	37
310	Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension, 1991, 9, 225-230.	0.5	65
311	Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris. American Journal of Cardiology, 1991, 68, 181-186.	1.6	19
312	Renal Hemodynamics and the Renin–Angiotensin–Aldosterone System in Normotensive Subjects with Hypertensive and Normotensive Parents. New England Journal of Medicine, 1991, 324, 1305-1311.	27.0	117
313	Adenosine induces renal vasodilation in primary hypertensive patients. Journal of Hypertension, 1991, 9, S216.	0.5	0
314	Is a high serum cholesterol level associated with longer survival in elderly hypertensives?. Journal of Hypertension, 1990, 8, 755-761.	0.5	45
315	Age-related effects of placebo and active treatment in patients beyond the age of 60 years: the need for a proper control group. Journal of Hypertension, 1990, 8, 997-1002.	0.5	8
316	Acute responses to urapidil in hypertensive persons. American Journal of Cardiology, 1989, 64, D22-D24.	1.6	2
317	Comparison of a vasodilating beta-blocker and a cardioselective beta-blocker in long-term treatment of hypertension: a European multicentre study. Journal of Hypertension, 1989, 7, S266-267.	0.5	2
318	Alpha-adrenoceptors and the kidney. Journal of Hypertension, 1988, 6, S21???24.	0.5	4
319	Stimulation of renin by blockade of $\hat{l}\pm 2$ -adrenoceptors in man. Journal of Hypertension, 1988, 6, S416-417.	0.5	6
320	Diuretics ??? a risk in the long-term treatment of hypertensive patients?. Journal of Hypertension, 1988, 6, 925-930.	0.5	14
321	Short- and long-term effects of ramipril in hypertension. American Journal of Cardiology, 1987, 59, D79-D82.	1.6	11
322	Index for Normalization of Blood Volume. Clinical Science, 1982, 63, 375s-377s.	0.0	6
323	Renal vascular tachyphylaxis to angiotensin II: Specificity of the response for angiotensin. Life Sciences, 1982, 30, 813-819.	4.3	12